



K072759

17 Hatidhar St., P.O.B 2499
Ra'anana 43665 Israel
Tel. + 972 (9) 7757122
Fax. +972 (9) 7485916
E-mail: info@medimop.com
www.medimop.com

510(k) summary for the VIAL2BAG
(as required by section 807.92)

510(k) Notification submitted by: Medimop Medical Projects Ltd.
17 Hatidhar St.
P.O. Box 2499
Ra'anana 43665
Israel
Phone: + 972 (9) 7757122
Fax: +972 (9) 7485916

Contact person: Nachum Naveh
Manager, Quality Assurance and Regulatory Affairs

Date Summary Prepared August 24, 2007

Trade Name: Vial2Bag

Classification name: General Hospital Class II, 80LHI
Per 21 CFR 880.5440 Intravascular administration set

Common device name: Same as Trade name

Predicate devices: ROBERTSITE VIAL ADAPTER
510(k) No. K040634
Halkey-Roberts
PHASEAL INFUSION ADAPTER
510(k) No. K980381
Carmel Pharma
TEVADAPTOR, DRUG RECONSTITUTION AND TRANSFER
SYSTEM 510(k) No. K051669
Teva

Manufacturer: Medimop Medical Projects Ltd.
17 Hatidhar St.
P.O. Box 2499
Ra'anana 43665
Israel

DEC 13 2007



K072759

17 Hatidhar St., P.O.B 2499
Ra'anana 43665 Israel
Tel. + 972 (9) 7757122
Fax. +972 (9) 7485916
E-mail: info@medimop.com
www.medimop.com

Material:

The Vial2Bag is composed of materials that were tested in accordance with the ISO 10993-1 standard and/or USP VI requirements and were determined suitable for the Indications for Use of this product.

Device Description:

The Vial2Bag is designed to serve as a connecting part between the IV bag and an external IV Line while allowing safe and easy transfer of drugs/diluents from and into an IV bag. The product allows quick transfer of the contents of a syringe or vial into an IV bag.

The Vial2Bag is an assembly of three components a spike, a Swabable valve and a twist-off.

Indications for Use:

The Vial2Bag is indicated to serve as a connecting part between the IV bag and an external IV Line. The Vial2Bag has a built in connector which makes it possible to admix drugs into the infusion solution using a Swabable Valve.

Technological comparison to Predicate Device:

The Vial2Bag has Indications for Use identical to the PhaSeal Infusion Adapter and similar to the TEVADAPTOR— all are intended for admixing drugs and diluents and add it to the contents of an IV bag. All products have multiple access valves and piercing spikes, which enable the users to create a direct passage from vials to IV bags (and vice-versa), in a sterile manner.

The Vial2Bag allows any standard accessory with a luer connection to be connected to the IV bag. Once mixing of the diluent and the drug is complete the drug solution can be transferred into the IV bag. This can be repeated several times. The Vial2Bag assembly is a single use device and should be disposed of with the IV bag.

All devices are packaged sterile and designed ergonomically.

Any differences between the Vial2Bag and the equivalent devices have no significant influence on safety or effectiveness.

Safety and Effectiveness:

All finished products are tested and must meet all required release specifications prior to distribution. The array of testing required for release include but are not limited to; Physical testing and visual examination (in-process and finished product).

Conclusion:

It is our conclusion that the Vial2Bag and its predicates are substantially equivalent in their Indications for Use, design, material, sterility and packaging.

The Vial2Bag is to be used in a similar manner to the predicate devices and introduces no new issues of safety and effectiveness.



DEC 13 2007

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Medimop Medical Projects, Limited
C/O Mr. Ari Y. Sobel
Director, Regulatory Affairs
West Pharmaceutical Services
101 Gordon Drive
Lionville, Pennsylvania 19341

Re: K072759

Trade/Device Name: Vial2Bag

Regulation Number: 21 CFR 880.5440

Regulation Name: Intravascular Administration Set

Regulatory Class: II

Product Code: LHI

Dated: September 17, 2007

Received: September 28, 2007

Dear Mr. Sobel:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Chiu Lin, Ph.D.

Director

Division of Anesthesiology, General Hospital,
Infection Control and Dental Devices

Office of Device Evaluation

Center for Devices and

Radiological Health


Enclosure

Indications for Use

510(k) Number (if known): K072759

Device Name: Vial2Bag

Indications for Use: The Vial2Bag is indicated to serve as a connecting part between the IV bag and an external IV Line. The Vial2Bag has a built in connector which makes it possible to admix drugs into the infusion solution using a Swabable Valve.



(Division Sign-Off)
Division of Anesthesiology, General Hospital
Infection Control, Dental Devices

510(k) Number: K072759

Prescription Use (Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use _____ (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Page ___ of ___